Key points are not available for this paper at this time.
Results of this trial suggest a benefit for EGFR/HER1 blockade with erlotinib in patients with HCC manifested by disease control. Additional studies with erlotinib as a single agent or in combination with other agents are warranted.
Philip et al. (Sat,) studied this question.